- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00811356
A First Time in Human Study in Healthy Volunteers to Investigate a New Medicine to Treat Malaria
A Single-Blind, Placebo-Controlled, Randomized First Time in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Dose Escalation of GSK932121 in Healthy Adult Subjects
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Malaria is a type of parasitic infection, common in tropical and subtropical regions of the world, including parts of the Americas, Asia, and Africa. In recent years there has been a rapid spread of drug resistant malaria which makes it necessary to develop new antimalarial treatments. In animal studies, GSK932121 is shown to be able to kill the malaria parasite and is fully active against drug resistant malaria parasites. It is hoped that information collected on this study will lead to an improved treatment for malaria.
This is a first time in human fusion study which has 3 parts:
Part A - single dose escalation/ food effect: a study where the study drug is given once only- first at the lowest dose of in a group of participants and the dose increased only if the previous dose is found to be safe. It also looks at the effect of food on the study drug in the body Part B - repeat dose escalation: a study where the study drug will be given daily for up to 7 days - first at a lower dose in a group of participants and the dose increased for the next group only if the previous dose is found to be safe and Part B - drug-drug interaction: a study where the study drug will be given daily for up to 7 days at a dose determined to be safe in previous groups of participants and looking at the effect of the study drug on other specific approved medications (such as rosiglitazone--a diabetic medication and rosuvastatin--a cholesterol lowering medication) in the body.
Safety will be assessed by measurement of vital signs, cardiac monitoring, spirometry, collection of adverse event assessments, renal biomarkers and laboratory safety tests.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 1
Kontakte und Standorte
Studienorte
-
-
Victoria
-
Melbourne, Victoria, Australien, 3004
- GSK Investigational Site
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Male or female between 18 and 50 years of age, inclusive
- Females of non-childbearing potential (as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea
- Body weight > 50 kg and BMI within the range 19 - 31 kg/m2 (inclusive)
- QTcB or QTcF < 450 msec; or QTc < 480 msec in subjects with Bundle Branch Block
Exclusion Criteria:
- Positive pre-study drug/alcohol screen
- Positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening.
- A positive test for HIV antibody
- History of regular alcohol consumption within 6 months of the study
- Participation in a clinical trial with an investigational product within 30 days or 5 half-lives of the investigational product (whichever is longer) prior to start of the new study
- Exposure to more than four new drugs or within 12 months prior to the first dosing day
- Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication
- History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that would be contraindicated
- Donation of blood or blood products in excess of 500 mL within a 56 day period.
- Pregnant females as determined by positive serum or urine hCG test at screening or prior to dosing.
- Lactating females.
- Unwillingness or inability to follow the procedures outlined in the protocol.
- History of sensitivity to heparin or history of heparin-induced thrombocytopenia if heparin is used to maintain the patency of an intravenous cannula.
- Asthma or a history of asthma
- Smoking or history or regular use of tobacco- or nicotine-containing products within 2 months prior to screening
- Consumption of red wine, seville oranges, grapefruit or grapefruit juice and/or pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior to the first dose of study medication.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Crossover-Aufgabe
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Single Dose, Repeat Dose, Drug-Drug Interaction
GSK932121 or placebo will be administered as a single dose with or without food in a dose escalation manner. Once the results from the single dose is obtained and reviewed, GSK932121 or placebo will be administered as a repeat dose. The results from each repeat dose level will be reviewed prior to determining the next repeat dose level. To better understand the effect of GSK932121 on rosiglitazone and rosuvastatin, a drug-drug interaction arm will also be investigated in this study. Rosiglitazone and rosuvastatin will be administered alone, then GSK932121 will be given as a repeat dose. Rosiglitazone and rosuvastatin will then be administered in combination with GSK932121. |
GSK932121 is the study drug that will be tested in all parts of this study as described above.
Rosiglitazone and rosuvastatin will only be tested in the drug-drug interaction substudy.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Evidence of safety as determined by assessing adverse events, vital signs, spirometry, ECGs, telemetry, renal biomarkers, safety labs, and physical examination
Zeitfenster: Part A: 3-4 months; Part B: ~1 month
|
Part A: 3-4 months; Part B: ~1 month
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
|---|---|
|
Plasma or blood concentrations of study drug
Zeitfenster: Part A: 3-4 months; Part B: ~1 month
|
Part A: 3-4 months; Part B: ~1 month
|
Mitarbeiter und Ermittler
Sponsor
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Infektionen
- Vektor-übertragene Krankheiten
- Parasitäre Krankheiten
- Protozoen-Infektionen
- Malaria
- Hypoglykämische Mittel
- Physiologische Wirkungen von Arzneimitteln
- Molekulare Mechanismen der pharmakologischen Wirkung
- Enzym-Inhibitoren
- Antimetaboliten
- Anticholesterämische Mittel
- Hypolipidämische Mittel
- Lipidregulierende Mittel
- Hydroxymethylglutaryl-CoA-Reduktase-Inhibitoren
- Rosuvastatin Calcium
- Rosiglitazon
Andere Studien-ID-Nummern
- 111319
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
Studiendaten/Dokumente
-
Studienprotokoll
Informationskennung: 111319Informationskommentare: For additional information about this study please refer to the GSK Clinical Study Register
-
Einwilligungserklärung
Informationskennung: 111319Informationskommentare: For additional information about this study please refer to the GSK Clinical Study Register
-
Statistischer Analyseplan
Informationskennung: 111319Informationskommentare: For additional information about this study please refer to the GSK Clinical Study Register
-
Datensatzspezifikation
Informationskennung: 111319Informationskommentare: For additional information about this study please refer to the GSK Clinical Study Register
-
Kommentiertes Fallberichtsformular
Informationskennung: 111319Informationskommentare: For additional information about this study please refer to the GSK Clinical Study Register
-
Klinischer Studienbericht
Informationskennung: 111319Informationskommentare: For additional information about this study please refer to the GSK Clinical Study Register
-
Einzelner Teilnehmerdatensatz
Informationskennung: 111319Informationskommentare: For additional information about this study please refer to the GSK Clinical Study Register
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Malaria
-
Medicines for Malaria VentureSwiss Tropical & Public Health Institute; Rinda Ubuzima, Rwanda; Swiss BioQuant; ACE ResearchNoch keine RekrutierungMalaria | Malaria-Infektion | Malaria-Prophylaxe | Malaria (Plasmodium Falciparum) | Malaria falciparum | Malaria-Parasitämie | Malaria -PräventionRuanda
-
Noguchi Memorial Institute for Medical ResearchMedical Research Center Unit The Gambia (MRCG)RekrutierungMalaria-Infektion | Malaria asymptomatische Parasitämie | Malaria falciparum | Malaria-ÜbertragungGhana
-
Medicines for Malaria VentureAsociacion Civil Selva AmazonicaAbgeschlossenPlasmodium falciparum Malaria | Plasmodium Vivax-MalariaPeru
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...AbgeschlossenVivax-Malaria | Falciparum-MalariaIndonesien
-
University of OxfordWellcome Trust; Ministry of public Health AfghanistanAbgeschlossenVivax-Malaria | Unkomplizierte Falciparum-MalariaAfghanistan
-
Menzies School of Health ResearchInternational Centre for Diarrhoeal Disease Research, Bangladesh; Addis Ababa... und andere MitarbeiterAbgeschlossenVerringerung des Risikos von P. vivax nach Falciparum-Infektionen in co-endemischen Gebieten (PRIMA)Malaria | Vivax-Malaria | Falciparum-MalariaÄthiopien, Bangladesch, Indonesien
-
University of California, San FranciscoCenters for Disease Control and Prevention; University of Massachusetts, Amherst und andere MitarbeiterZurückgezogenPlasmodium falciparum Malaria | Plasmodium Vivax-MalariaLaos
-
Gadjah Mada UniversityMenzies School of Health Research; Eijkman Institute for Molecular Biology; Timika...AbgeschlossenPlasmodium falciparum Malaria | Plasmodium Vivax-MalariaIndonesien
-
London School of Hygiene and Tropical MedicineWorld Health Organization; United Nations High Commissioner for Refugees; HealthNet... und andere MitarbeiterAbgeschlossenMalaria | Vivax-Malaria | Falciparum-MalariaPakistan
-
Menzies School of Health ResearchNational Health and Medical Research Council, Australia; Wellcome Trust; National...AbgeschlossenVivax-Malaria | Falciparum-MalariaIndonesien
Klinische Studien zur GSK932121; Rosiglitazone; Rosuvastatin
-
University of CalgaryGlaxoSmithKlineBeendet
-
GlaxoSmithKlineBeendetAlzheimer-KrankheitAustralien, Spanien, Vereinigte Staaten, Bulgarien, Deutschland, Belgien, Kanada, Hongkong, Korea, Republik von, Portugal, Argentinien, Chile, Griechenland, Slowenien, Tschechien, Frankreich, Ungarn, Italien, Südafrika, Indien, ... und mehr
-
GlaxoSmithKlineAbgeschlossen
-
GlaxoSmithKlineAbgeschlossenAlzheimer-KrankheitVereinigte Staaten, Australien, Spanien, Bulgarien, Polen, Deutschland, Philippinen, Singapur, Belgien, Kanada, Hongkong, Korea, Republik von, Finnland, Slowenien, Tschechien, Frankreich, Südafrika, Schweden, Niederlande, Mala... und mehr
-
Korea University Anam HospitalAbgeschlossenMetabolisches SyndromKorea, Republik von
-
GlaxoSmithKlineAbgeschlossen
-
GlaxoSmithKlineAbgeschlossenDiabetes mellitus, Typ 2Spanien, Deutschland, Frankreich, Österreich, Italien
-
National Cheng-Kung University HospitalAbgeschlossenKoronare Herzkrankheit | Insulinresistenz | Glukose Intoleranz | Prädiabetes
-
GlaxoSmithKlineAbgeschlossen
-
National Heart, Lung, and Blood Institute (NHLBI)AbgeschlossenKongestive HerzinsuffizienzVereinigte Staaten